NRx Pharmaceuticals (NASDAQ:NRXP) Announces Quarterly Earnings Results, Beats Expectations By $0.16 EPS

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.16, Zacks reports.

NRx Pharmaceuticals Stock Down 1.8%

NASDAQ:NRXP traded down $0.04 on Monday, hitting $2.15. The stock had a trading volume of 726,308 shares, compared to its average volume of 1,113,704. The company has a fifty day moving average price of $2.82 and a two-hundred day moving average price of $2.96. NRx Pharmaceuticals has a 1-year low of $1.62 and a 1-year high of $5.05. The stock has a market cap of $93.84 million, a price-to-earnings ratio of -3.91 and a beta of 2.11.

Analyst Upgrades and Downgrades

NRXP has been the topic of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Tuesday, November 3rd. UBS Group restated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 26th. HC Wainwright restated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Tuesday, August 25th. Zacks Research cut NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 26th. Finally, Wall Street Zen downgraded NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Six analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

Check Out Our Latest Report on NRx Pharmaceuticals

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company’s candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.

Read More

Earnings History for NRx Pharmaceuticals (NASDAQ:NRXP)

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.